Last edition
News about "Eisai "
Eisai Signs Deal to Develop Tasurgratinib in Greater China Region with SciClone
Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched.
Eisai | 01/03/2025 | By Aishwarya
Leqembi sBLA for Alzheimers IV Maintenance Moves Forward with FDA
Eisai has submitted a supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb intravenous (IV) maintenance dosing to the US Food and Drug Administration (FDA).
Eisai | 01/04/2024 | By Manvi | 228
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy